{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T05:07:57Z","timestamp":1732943277167,"version":"3.30.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,28]]},"DOI":"10.7759\/cureus.74703","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:48:47Z","timestamp":1732855727000},"source":"Crossref","is-referenced-by-count":0,"title":["Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy"],"prefix":"10.7759","author":[{"given":"Taro","family":"Edahiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takero","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek M","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018, 391:1524-37. 10.1016\/S0140-6736(18)30422-7","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.246","article-title":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group","volume":"31","author":"Hoechstetter MA","year":"2017","unstructured":"Hoechstetter MA, Busch R, Eichhorst B, et al.. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group. Leukemia. 2017, 31:2833-7. 10.1038\/leu.2017.246","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson FK","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011, 118:4313-20. 10.1182\/blood-2011-06-338855","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger JA","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al.. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015, 373:2425-37. 10.1056\/NEJMoa1509388","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman JP","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al.. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet. 2020, 395:1278-91. 10.1016\/S0140-6736(20)30262-2","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020282","article-title":"Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs","volume":"12","author":"Vitale C","year":"2020","unstructured":"Vitale C, Montalbano MC, Salvetti C, Boccellato E, Griggio V, Boccadoro M, Coscia M. Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs. Cancers (Basel). 2020, 12:282. 10.3390\/cancers12020282","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.153064","article-title":"Peripheral neuropathies in chronic lymphocytic leukemia: A single center experience on 816 patients","volume":"102","author":"Briani C","year":"2017","unstructured":"Briani C, Visentin A, Salvalaggio A, et al.. Peripheral neuropathies in chronic lymphocytic leukemia: A single center experience on 816 patients. Haematologica. 2017, 102:e140-3. 10.3324\/haematol.2016.153064","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.10.005","article-title":"Spectrum of neurologic complications in chronic lymphocytic leukemia","volume":"12","author":"Lopes da Silva R","year":"2012","unstructured":"Lopes da Silva R. Spectrum of neurologic complications in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012, 12:164-79. 10.1016\/j.clml.2011.10.005","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000358292","article-title":"Successful treatment of refractory Guillain-Barr\u00e9 syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia","volume":"132","author":"Tzachanis D","year":"2014","unstructured":"Tzachanis D, Hamdan A, Uhlmann EJ, Joyce RM. Successful treatment of refractory Guillain-Barr\u00e9 syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia. Acta Haematol. 2014, 132:240-3. 10.1159\/000358292","journal-title":"Acta Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-020-00064-2","article-title":"Diagnosis of peripheral neuropathy","volume":"2","author":"Lehmann HC","year":"2020","unstructured":"Lehmann HC, Wunderlich G, Fink GR, Sommer C. Diagnosis of peripheral neuropathy. Neurol Res Pract. 2020, 2:20. 10.1186\/s42466-020-00064-2","journal-title":"Neurol Res Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-023-01249-3","article-title":"Central and peripheral nervous system complications of vasculitis syndromes from pathology to bedside: Part 2-Peripheral nervous system","volume":"23","author":"Mansueto G","year":"2023","unstructured":"Mansueto G, Lanza G, Falleti J, et al.. Central and peripheral nervous system complications of vasculitis syndromes from pathology to bedside: Part 2-Peripheral nervous system. Curr Neurol Neurosci Rep. 2023, 23:83-107. 10.1007\/s11910-023-01249-3","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000300","article-title":"Optic neuropathy due to chronic lymphocytic leukemia proven with optic nerve sheath biopsy","volume":"36","author":"Khan K","year":"2016","unstructured":"Khan K, Malik AI, Almarzouqi SJ, Morgan ML, Yalamanchili S, Chevez-Barrios P, Lee AG. Optic neuropathy due to chronic lymphocytic leukemia proven with optic nerve sheath biopsy. J Neuroophthalmol. 2016, 36:61-6. 10.1097\/WNO.0000000000000300","journal-title":"J Neuroophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000119235","article-title":"Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases","volume":"44","author":"Zaja F","year":"2003","unstructured":"Zaja F, Vianelli N, Sperotto A, et al.. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma. 2003, 44:1951-5. 10.1080\/1042819031000119235","journal-title":"Leuk Lymphoma"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/319017-acalabrutinib-and-obinutuzumab-for-chronic-lymphocytic-leukemia-complicated-with-peripheral-neuropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:48:49Z","timestamp":1732855729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/319017-acalabrutinib-and-obinutuzumab-for-chronic-lymphocytic-leukemia-complicated-with-peripheral-neuropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.74703","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}